Philip A Poole-Wilson

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
  2. ncbi request reprint A commentary on clinical trials in chronic heart failure
    Philip A Poole-Wilson
    Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    Semin Cardiothorac Vasc Anesth 10:242-5. 2006
  3. ncbi request reprint Commentary on the Carvedilol or Metoprolol European Trial (COMET)
    Philip A Poole-Wilson
    National Heart and Lung Institute and Faculty of Medicine, Imperial College London, London, United Kingdom
    Am J Cardiol 93:40B-2B. 2004
  4. doi request reprint Rheumatic fever: the potential advantages of technology
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Nat Clin Pract Cardiovasc Med 5:426-7. 2008
  5. ncbi request reprint Patients who have dilated cardiomyopathy must have a trial of bridge to recovery: the case against that proposition
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College London, London, UK
    Heart Fail Clin 3:317-9. 2007
  6. ncbi request reprint New therapies for the management of acute heart failure
    Philip A Poole-Wilson
    Department of Cardiac Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK
    Curr Cardiol Rep 5:229-36. 2003
  7. ncbi request reprint The prevention of cardiovascular disease worldwide: whose task and WHO's task?
    Philip Poole-Wilson
    National Heart and Lung Institute, Faculty of Medicine, Imperial College, London
    Clin Med 5:379-84. 2005
  8. ncbi request reprint Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial
    Philip A Poole-Wilson
    Cardiac Medicine, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Lancet 364:849-57. 2004
  9. pmc Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial
    P A Poole-Wilson
    Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Heart 92:1473-9. 2006
  10. doi request reprint Differences in European and North American approaches to the management of heart failure
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Cardiol Clin 26:107-12, viii. 2008

Collaborators

Detail Information

Publications85

  1. ncbi request reprint Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
    ..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
  2. ncbi request reprint A commentary on clinical trials in chronic heart failure
    Philip A Poole-Wilson
    Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    Semin Cardiothorac Vasc Anesth 10:242-5. 2006
    ..Most trials have included patients 10 years younger than those in the general population. There is little evidence for efficacy in patients with a near normal ejection fraction. Few women have been included in trials...
  3. ncbi request reprint Commentary on the Carvedilol or Metoprolol European Trial (COMET)
    Philip A Poole-Wilson
    National Heart and Lung Institute and Faculty of Medicine, Imperial College London, London, United Kingdom
    Am J Cardiol 93:40B-2B. 2004
    ..These data indicate that cardiovascular benefit may be obtained from switching patients from metoprolol tartrate to carvedilol...
  4. doi request reprint Rheumatic fever: the potential advantages of technology
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Nat Clin Pract Cardiovasc Med 5:426-7. 2008
    ....
  5. ncbi request reprint Patients who have dilated cardiomyopathy must have a trial of bridge to recovery: the case against that proposition
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College London, London, UK
    Heart Fail Clin 3:317-9. 2007
    ....
  6. ncbi request reprint New therapies for the management of acute heart failure
    Philip A Poole-Wilson
    Department of Cardiac Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK
    Curr Cardiol Rep 5:229-36. 2003
    ..These are small but important advances that increase our knowledge of the pathophysiology of acute heart failure, and also provide an indication of which drugs are preferable for the treatment of this distressing condition...
  7. ncbi request reprint The prevention of cardiovascular disease worldwide: whose task and WHO's task?
    Philip Poole-Wilson
    National Heart and Lung Institute, Faculty of Medicine, Imperial College, London
    Clin Med 5:379-84. 2005
    ..Too many vested interests obstruct progress in the prevention of cardiovascular disease...
  8. ncbi request reprint Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial
    Philip A Poole-Wilson
    Cardiac Medicine, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Lancet 364:849-57. 2004
    ..We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris...
  9. pmc Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial
    P A Poole-Wilson
    Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Heart 92:1473-9. 2006
    ..To determine whether, in acute non-ST elevation coronary syndrome, the benefit from early invasive coronary intervention compared with a conservative strategy of later symptom-guided intervention varies over time...
  10. doi request reprint Differences in European and North American approaches to the management of heart failure
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Cardiol Clin 26:107-12, viii. 2008
    ..Current recommendations can be confusing and often do not reflect the complexities of modern personalized medicine...
  11. ncbi request reprint Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, Dovehouse Street, London, SW3 6LY, UK
    Eur J Heart Fail 4:321-9. 2002
    ..The target dose for carvedilol is 25 mg bid and for metoprolol tartrate 50 mg bid. This manuscript outlines the rationale, design and possible outcomes of COMET...
  12. ncbi request reprint Heart rate response during exercise predicts survival in adults with congenital heart disease
    Gerhard Paul Diller
    Adult Congenital Heart Program, Department of Cardiology, Royal Brompton Hospital, London, United Kingdom
    J Am Coll Cardiol 48:1250-6. 2006
    ..To assess the prognostic value of heart rate response to exercise in adult congenital heart disease (ACHD) patients...
  13. ncbi request reprint The cardiac component of cardiac cachexia
    Viorel G Florea
    Department of Cardiac Medicine, National Heart and Lung Institute, London, United Kingdom
    Am Heart J 144:45-50. 2002
    ..This study sought to assess the cardiac dimensions, mass, and function and changes in these parameters over time in patients with chronic heart failure with and without cachexia...
  14. ncbi request reprint Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data
    Philip A Poole-Wilson
    Cardiac Medicine, Imperial College, Dovehouse Street, London SW3 6LY, UK
    J Clin Epidemiol 60:727-33. 2007
    ..Published clinical trial data rarely allow assessment of the health care resource utilization implications of treatment. We give an example of how these can be assessed given appropriate tabulation of data...
  15. ncbi request reprint Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease
    Rakesh Sharma
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    Am J Cardiol 92:188-93. 2003
    ..Congenital heart disease in adults may be amenable to novel anti-inflammatory therapies in selected patients...
  16. ncbi request reprint Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial
    Rakesh Sharma
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
    Eur Heart J 25:1021-8. 2004
    ..We aimed to investigate the relationship between the concentration of haemoglobin and survival in CHF...
  17. ncbi request reprint Cellular endotoxin desensitization in patients with severe chronic heart failure
    Rakesh Sharma
    Clinical Cardiology, NHLI, Imperial College School of Medicine, London, UK
    Eur J Heart Fail 7:865-8. 2005
    ..It is not known if LPS desensitization occurs in CHF...
  18. ncbi request reprint Haemoglobin concentration and prognosis in new cases of heart failure
    Paul R Kalra
    National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    Lancet 362:211-2. 2003
    ..The adverse effects of anaemia on survival might be a consequence of chronic heart failure rather than a separate process causing disease progression...
  19. doi request reprint Cardiothoracic ratio from postero-anterior chest radiographs: a simple, reproducible and independent marker of disease severity and outcome in adults with congenital heart disease
    Konstantinos Dimopoulos
    Royal Brompton Hospital, London, UK
    Int J Cardiol 166:453-7. 2013
    ..The aim of this study was to assess the prognostic potential of cardiothoracic ratio, a simple marker of cardiomegaly, in a large cohort of ACHD...
  20. ncbi request reprint The development of heart failure in patients with stable angina pectoris
    George C Sutton
    Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur J Heart Fail 9:234-42. 2007
    ..To describe the clinical characteristics of patients with stable angina pectoris who develop heart failure and the events preceding its onset...
  21. ncbi request reprint Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival
    Konstantinos Dimopoulos
    Adult Congenital Heart Programme, Department of Cardiology, Royal Brompton Hospital, Sydney St, London, SW3 6NP, United Kingdom
    Circulation 113:2796-802. 2006
    ..We sought to establish the distribution, relation to cyanosis, and prognostic value of the V(E)/V(CO2) slope across a wide spectrum of ACHD patients...
  22. ncbi request reprint Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors
    Stephan von Haehling
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
    Am J Cardiol 95:885-9. 2005
    ..This study demonstrated that noradrenaline and isoproterenol inhibit TNF-alpha production in patients with CHF in ex vivo whole blood in a dose-dependent fashion. The beta-blocker bisoprolol abolishes this effect...
  23. doi request reprint Anemia in adults with congenital heart disease relates to adverse outcome
    Konstantinos Dimopoulos
    Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom
    J Am Coll Cardiol 54:2093-100. 2009
    ..To assess the relation of anemia in noncyanotic adults with congenital heart disease (ACHD) to functional capacity and mortality...
  24. ncbi request reprint Association of deranged adrenal steroid metabolism with anemia in chronic heart failure
    Darlington O Okonko
    Clinical Cardiology, National Heart and Lung Institute, Imperial College, London, UK
    Am J Cardiol 96:101-3. 2005
    ..The cortisol/DHEA ratio was independently and inversely associated with hemoglobin concentrations, suggesting that alterations of the steroid milieu may play a role in the pathogenesis of anemia in CHF...
  25. doi request reprint Adaptive servo-ventilation in heart failure patients with sleep apnea: a real world study
    Peter C Hastings
    Clinical and Academic Unit of Sleep and Breathing, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK
    Int J Cardiol 139:17-24. 2010
    ..We hypothesized that ASV would be effective at reducing sleep apnea and improving both cardiac status and quality of life...
  26. doi request reprint Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial
    Darlington O Okonko
    Clinical Cardiology, NHLI, Imperial College London, London, United Kingdom
    J Am Coll Cardiol 51:103-12. 2008
    ..We tested the hypothesis that intravenous iron improves exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure (CHF) and iron deficiency...
  27. doi request reprint Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unknown origin: evidence of an immune basis
    Darlington O Okonko
    Clinical Cardiology, National Heart and Lung Institute, Imperial College, London, UK
    Int J Cardiol 166:664-71. 2013
    ..We tested the hypothesis that unexplained anaemia in CHF might be subsequent to diminished erythropoiesis as a result of an immune-mediated suppression of erythroid colony formation...
  28. ncbi request reprint Safety of nifedipine GITS in stable angina: the ACTION trial
    Philip A Poole-Wilson
    Department of Cardiac Medicine, Imperial College, London, UK
    Cardiovasc Drugs Ther 20:45-54. 2006
    ..9 years...
  29. ncbi request reprint QT dispersion has no prognostic value in patients with symptomatic heart failure: an ELITE II substudy
    Yi Gang
    Department of Cardiological Sciences, St George s Hospital Medical School, Cranmer Terrace, London, SW17 0RE, United Kingdom
    Pacing Clin Electrophysiol 26:394-400. 2003
    ..In conclusion, increased QT dispersion is not associated with increased mortality in patients with heart failure, and is not suitable to examine drug efficacy in these patients...
  30. ncbi request reprint Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
    Marcus D Flather
    Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Trust, London, UK
    Eur Heart J 26:215-25. 2005
    ..The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients >/=70 years, regardless of ejection fraction...
  31. doi request reprint Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival
    Darlington O Okonko
    Clinical Cardiology, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    J Am Coll Cardiol 58:1241-51. 2011
    ..The aim of this study was to comprehensively delineate iron metabolism and its implications in patients with chronic heart failure (CHF)...
  32. ncbi request reprint Clinical course of isolated stable angina due to coronary heart disease
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur Heart J 28:1928-35. 2007
    ..To describe the clinical course of patients with stable angina due to coronary heart disease without a history of cardiovascular (CV) events or revascularization (isolated angina)...
  33. ncbi request reprint Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication
    Gerhard Paul Diller
    Adult Congenital Heart Program, Department of Cardiology, Royal Brompton Hospital, London, UK
    Circulation 112:828-35. 2005
    ....
  34. doi request reprint Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction
    Darlington O Okonko
    Clinical Cardiology, National Heart and Lung Institute, Imperial College, London, UK
    Int J Cardiol 164:359-64. 2013
    ..We tested the hypothesis that this might be due to Epo resistance and investigated whether any defects apparent were due to Epo receptor (EpoR) downregulation and/or impaired Epo-induced signal transduction...
  35. ncbi request reprint Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins
    Rakesh Sharma
    Clinical Cardiology, NHLI, Imperial College School of Medicine, Dovehouse Street, SW3 6LY, London, UK
    Eur J Heart Fail 7:479-84. 2005
    ..We sought to investigate the relationship between whole blood endotoxin responsiveness and serum lipoprotein concentrations. It is not known if low-dose LPS is sufficient to stimulate immune activation...
  36. ncbi request reprint Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure
    Gabor Foldes
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    Int J Cardiol 124:80-5. 2008
    ..Innate immune activation mediated by myocardial Toll-like receptors (TLRs) is involved in cardiovascular disease. The function and role of TLRs on peripheral leukocytes in human chronic heart failure (CHF) are not known...
  37. doi request reprint Hyponatraemia: A strong predictor of mortality in adults with congenital heart disease
    Konstantinos Dimopoulos
    Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK
    Eur Heart J 31:595-601. 2010
    ..We studied the prevalence of hyponatraemia and its prognostic implications in a large population of adult patients with congenital heart disease (ACHD)...
  38. ncbi request reprint ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic
    Philip A Poole-Wilson
    Division of Cardiac Medicine, Imperial College Faculty of Medicine, National Heart and Lung Institute, London, United Kingdom
    Med Clin North Am 87:373-89. 2003
    ..If further studies provide more support for the idea that ACE inhibitors prevent ischemic episodes and delay the onset of heart failure, then a new indication for ACE inhibitors will be the prevention of heart failure...
  39. ncbi request reprint The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle
    Thomas Thum
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College of Medicine, London, United Kingdom
    J Am Coll Cardiol 46:1799-802. 2005
    ..This leads to reduced scar formation, repressed myocardial apoptosis, and improved cardiac outcome...
  40. doi request reprint C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure
    Paul R Kalra
    Department of Clinical Cardiology, National Heart and Lung Institute, London SE3 6LY, UK
    Clin Sci (Lond) 118:71-7. 2010
    ..5 and 15.7+/-6.0 pg/ml (P=0.01). In conclusion, CNP is synthesized and secreted into the circulation by the normal human kidney, where it may have paracrine actions. Net renal secretion of CNP appears to be blunted in patients with CHF...
  41. ncbi request reprint Mechanism of cardiac output gain from cardiac resynchronization therapy in patients with coronary artery disease or idiopathic dilated cardiomyopathy
    Tushar V Salukhe
    National Heart and Lung Institute, Royal Brompton Hospital, London, United Kingdom
    Am J Cardiol 97:1358-64. 2006
    ..Second, little of this increment in CO is achieved by AV delay shortening alone. Third, under native activation, long t-IVT during peak stress is the single best predictor of resynchronization-mediated increment in peak stress CO...
  42. ncbi request reprint Chronic heart failure patients with restrictive LV filling pattern have significantly less benefit from cardiac resynchronization therapy than patients with late LV filling pattern
    Tushar V Salukhe
    National Heart Lung Institute, Royal Brompton Hospital, Sydney Street, London SW3 6 NP, UK
    Int J Cardiol 100:5-12. 2005
    ..Indeed, the very mechanism of benefit from resynchronization is controversial. Resynchronization may work by improving ventricular filling: we tested the hypothesis that benefit from resynchronization depends on filling pattern...
  43. ncbi request reprint Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study
    Stefan D Anker
    Applied Cachexia Research, Department of Cardiology, Charite, Campus Virchow Klinikum, Berlin, Germany
    Lancet 361:1077-83. 2003
    ..We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors...
  44. ncbi request reprint Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients
    Stefan D Anker
    Applied Cachexia Research, Department of Cardiology, Charite Campus Virchow Klinikum, Berlin, Germany
    Int J Cardiol 112:234-42. 2006
    ..Treatment with statins may lead to a lower mortality in CHF, independent of cholesterol levels, CHF etiology and clinical status...
  45. ncbi request reprint Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy
    Ravi G Assomull
    Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, United Kingdom
    J Am Coll Cardiol 48:1977-85. 2006
    ..We studied the prognostic implications of midwall fibrosis in dilated cardiomyopathy (DCM) in a prospective longitudinal study...
  46. ncbi request reprint Stress (Takotsubo) cardiomyopathy--a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning
    Alexander R Lyon
    Department of Cardiac Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK
    Nat Clin Pract Cardiovasc Med 5:22-9. 2008
    ..This effect is greatest at the apical myocardium, in which the beta-adrenoceptor density is greatest. Our hypothesis has implications for the use of drugs or devices in the treatment of patients with stress cardiomyopathy...
  47. ncbi request reprint The pathologic basis of Q-wave and non-Q-wave myocardial infarction: a cardiovascular magnetic resonance study
    James C C Moon
    Centre for Advanced Magnetic Resonance in Cardiology CAMRIC, Royal Brompton Hospital, London, United Kingdom
    J Am Coll Cardiol 44:554-60. 2004
    ..The purpose of this study was to determine the pathologic basis of Q-wave (QW) and non-Q-wave (NQW) myocardial infarction (MI)...
  48. pmc SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure
    Alexander R Lyon
    National Heart and Lung Institute, Imperial College, London, United Kingdom
    Circ Arrhythm Electrophysiol 4:362-72. 2011
    ..A critical question is whether SERCA2a gene therapy predisposes to increased sarcoplasmic reticulum calcium (SR Ca(2+)) leak, cellular triggered activity, and ventricular arrhythmias in the failing heart...
  49. doi request reprint Variation in severity and type of sleep-disordered breathing throughout 4 nights in patients with heart failure
    Ali Vazir
    Clinical and Academic Unit of Sleep and Breathing, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College, Sydney Street, London SW3 6NP, UK
    Respir Med 102:831-9. 2008
    ..Currently there is good evidence for treatment of obstructive sleep apnea (OSA) in CHF with continuous positive airway pressure; however, for central sleep apnea (CSA) the treatment is less clear...
  50. ncbi request reprint Effect of anemia on exercise tolerance in chronic heart failure in men
    Paul R Kalra
    Clinical Cardiology, National Heart and Lung Institute, London, United Kingdom
    Am J Cardiol 91:888-91. 2003
  51. ncbi request reprint Future strategies of reverse remodeling: summation
    Philip A Poole-Wilson
    Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College of Science, Technology, and Medicine, London, England
    J Card Fail 8:S556-61. 2002
  52. ncbi request reprint The safety of amiodarone in patients with heart failure
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    J Card Fail 13:340-5. 2007
    ..Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure...
  53. ncbi request reprint Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:901-9. 2007
    ..We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a HF hospitalisation in COMET...
  54. ncbi request reprint Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions
    Jacobus Lubsen
    SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
    J Clin Epidemiol 60:720-6. 2007
    ..Whether blood pressure (BP) reduction is a necessary prerequisite for cardiovascular risk reduction or an epiphenomenon has not been definitively established. We used an innovative analytic method to address this question...
  55. ncbi request reprint Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial
    Daniela Dobre
    Department of Clinical Pharmacology, University Medical Centre Groningen, University of Groningen, The Netherlands
    Am Heart J 154:109-15. 2007
    ..We aimed to assess tolerability and dose-related effects of the beta-blocker nebivolol in elderly patients from the SENIORS trial...
  56. doi request reprint Focus on mechanical assist devices for the treatment of heart failure
    Philip A Poole-Wilson
    Nat Clin Pract Cardiovasc Med 5:59. 2008
  57. ncbi request reprint Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre Madrid, Spain
    J Hypertens 25:1711-8. 2007
    ..Little data is available concerning the prognostic implications of renal function abnormalities, their evolution over time and the effects of nifedipine on such abnormalities in patients with stable angina pectoris...
  58. ncbi request reprint [Universal definition of the myocardial infarction]
    Kristian Thygesen
    Department of Medicine and Cardiology, Aarhus University Hospital, Dania
    Kardiol Pol 66:47-62. 2008
  59. ncbi request reprint Chronic heart failure
    Philip A Poole-Wilson
    Timely Top Med Cardiovasc Dis 11:E2. 2007
  60. ncbi request reprint Prediction of mode of death in heart failure: the Seattle Heart Failure Model
    Dariush Mozaffarian
    Harvard Medical School and Harvard School of Public Health, Boston, Mass, USA
    Circulation 116:392-8. 2007
    ..Prediction of mode of death may facilitate decisions about specific medications or devices...
  61. ncbi request reprint Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study
    Anthony M Dart
    Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria, Australia
    Eur J Echocardiogr 8:275-83. 2007
    ..To evaluate the relationship between echocardiographic cardiac function and outcome in patients with stable symptomatic angina...
  62. ncbi request reprint Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    Am Heart J 150:123-31. 2005
    ..We compared effects of losartan to captopril on mortality, morbidity, and functional status for patients in the ELITE II study...
  63. ncbi request reprint Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Eur Heart J 26:2259-68. 2005
    ....
  64. ncbi request reprint Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
    Andrea Di Lenarda
    Department of Cardiology, Ospedale di Cattinara, Strada di Fiume 447, 34100 Trieste, Italy
    Eur J Heart Fail 7:640-9. 2005
    ..metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol...
  65. ncbi request reprint Symptoms in patients with heart failure are prognostic predictors: insights from COMET
    Inger Ekman
    Institute of Nursing, Sahlgrenska Academy at Goteborg University, SE 405 30 Goteborg, Sweden
    J Card Fail 11:288-92. 2005
    ....
  66. ncbi request reprint Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    Am Heart J 149:370-6. 2005
    ..Beta-blockers with different receptor bindings reduce mortality in patients with chronic heart failure. We compared the effects of the beta1-blocker metoprolol tartrate and the beta1-, beta2-, and alpha1-blocker carvedilol...
  67. ncbi request reprint Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom
    Federica de Giuli
    Salvatore Maugeri Foundation, IRCCS, Gussago Brescia, Italy
    Eur J Heart Fail 7:295-302. 2005
    ..There are few large population-based studies of the incidence and outcome of heart failure where the diagnosis of heart failure (HF) has been made by a General Practitioner (GP) in the community...
  68. ncbi request reprint Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
    Jacobus Lubsen
    SOCAR Research SA, Nyon, Switzerland
    J Hypertens 23:641-8. 2005
    ..To examine the effects of nifedipine GITS on clinical outcome in patients with concurrent stable angina and hypertension...
  69. ncbi request reprint Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue
    Mariantonietta Cicoira
    Divisione Clinicizzata di Cardiologia, Universita degli Studi di Verona, Italy
    J Card Fail 10:421-6. 2004
    ..We hypothesized that correcting pVO2 for lean tissue rather than total body weight would improve the prediction of prognosis in patients with chronic heart failure (CHF)...
  70. ncbi request reprint A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
    John G F Cleland
    University of Hull, Kingston upon Hull, UK
    Cardiovasc Drugs Ther 18:139-52. 2004
    ..The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics...
  71. ncbi request reprint Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
    Philip A Poole-Wilson
    Lancet 359:2199; author reply 2203-4. 2002
  72. pmc Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients
    Tim C Clayton
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 331:869. 2005
    ..To derive a risk score for the combination of death from all causes, myocardial infarction, and disabling stroke in patients with stable symptomatic angina who require treatment for angina and have preserved left ventricular function...
  73. ncbi request reprint Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy
    Stefano Ghio
    Division of Cardiology, IRCCS Policlinico San Matteo, Pavia, Italy
    Eur Heart J 27:562-8. 2006
    ..An echocardiographic substudy was designed to evaluate the effects of nebivolol on systolic and diastolic left ventricular (LV) function in patients stratified according to the presence or absence of systolic LV dysfunction...
  74. ncbi request reprint The Seattle Heart Failure Model: prediction of survival in heart failure
    Wayne C Levy
    University of Washington, Seattle, WA 98177, USA
    Circulation 113:1424-33. 2006
    ....
  75. ncbi request reprint A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy
    Fernando A Botoni
    Postgraduate Course of Tropical Medicine, University Hospital, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Am Heart J 153:544.e1-8. 2007
    ..The objective of this study was to determine the safety and efficacy of renin-angiotensin system (RAS) inhibitors and beta-blockers in chronic Chagas cardiomyopathy...
  76. ncbi request reprint Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
    ..We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study...
  77. ncbi request reprint Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial
    Piotr Ponikowski
    Cardiac Department, Military Hospital, Wroclaw, Poland
    J Am Coll Cardiol 49:753-62. 2007
    ..This study sought to investigate whether darbepoetin alfa, an erythropoiesis-stimulating protein (ESP), improves exercise capacity in patients with symptomatic chronic heart failure (CHF) and anemia...
  78. pmc Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen NV, Denmark
    Heart 93:968-73. 2007
    ..Beta blocker treatment may worsen glucose metabolism...
  79. ncbi request reprint Cardiovascular health in Europe: a global problem
    Philip A Poole-Wilson
    J Am Coll Cardiol 49:117-9. 2007
  80. ncbi request reprint Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival
    Ewa A Jankowska
    Cardiology Department, Military Hospital, ul Weigla 5, 50 981 Wroclaw, Poland
    Circulation 114:1829-37. 2006
    ....
  81. ncbi request reprint Tracking coronary calcification and atherosclerotic lesions in patients with stable angina pectoris undergoing nifedipine therapy
    Michael Motro
    Sheba Medical Center, Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel
    Cardiology 107:165-71. 2007
    ....
  82. ncbi request reprint Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease
    Jan Erik Otterstad
    Hospital of Vestfold, Toensberg, Norway
    Scand Cardiovasc J 40:152-9. 2006
    ..Evaluate the prevalence, incidence and impact on prognosis of existing and new onset atrial fibrillation (AF) in patients with stable, symptomatic coronary artery disease...
  83. ncbi request reprint The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, 47 83 bld de l Hôpital, Paris, France
    Eur Heart J 27:1440-6. 2006
    ..Anaemia is a common comorbidity in chronic heart failure (CHF). The predictors of new onset anaemia (NOA) and its long-term prognostic value, particularly in patients treated with beta-blockers, are not known...
  84. ncbi request reprint A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
    John G F Cleland
    Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
    J Am Coll Cardiol 47:1603-11. 2006
    ..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
  85. ncbi request reprint Circulatory support for long-term treatment of heart failure: experience with an intraventricular continuous flow pump
    Stephen Westaby
    Oxford Heart Centre, Oxford, UK
    Circulation 105:2588-91. 2002
    ..After extensive laboratory testing, we began clinical trials with an axial flow pump for long-term treatment of New York Heart Association class IV, transplant-ineligible patients...